Progress in research on the correlation between Toxoplasma gondii infection and schizophrenia

doi:10.12140/j.issn.1000-7423.2019.01.019

Abstract

Abstract:

Toxoplasma gondii infection is one of the most common opportunistic infections in acquired immune deficiency syndrome patients. In addition to the pathogenesis directly caused by the infection, it has been found that T. gondii infection is related to the onset and progression of schizophrenia in recent years. Many studies have shown that Toxoplasma infection may affect the pathogenesis and progression of schizophrenia by damaging the nervous system, affecting neurotransmitters and the immune system. However, the specific mechanism underlying this correlation is still unclear. Understanding the intrinsic relationship between Toxoplasma infection and schizophrenia will help to interpret the pathogenesis and influencing factors of schizophrenia and provide a new direction for the prevention and treatment of schizophrenia. This article aims to review the progress in research on the correlation between T. gondii infection and schizophrenia.

Key words: Toxoplasma gondii, Schizophrenia, Acquired immune deficiency syndrome, Opportunistic infection

CLC Number:

R382.5

Jing OUYANG, Yao-kai CHEN. Progress in research on the correlation between Toxoplasma gondii infection and schizophrenia[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2019, 37(1): 102-106.

References 38

[1]	邹彩艳, 何军, 尹继, 等. 贵州省抑郁症患者刚地弓形虫感染状况调查及其基因型鉴定[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(4): 355-360.
[2]	姚礼捷, 彭鸿娟. 弓形虫抑制γ干扰素依赖的宿主细胞免疫的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(5): 503-508.
[3]	Sagud M, Vlatkovic S, Svob Strac D, et al. Latent Toxoplasma gondii infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia[J]. Compr Psychiatry, 2018, 82: 115-120.
[4]	Hernandez AV, Thota P, Pellegrino D, et al. A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option[J]. HIV Med, 2017, 18(2): 115-124.
[5]	Davis J, Eyre H, Jacka FN, et al. A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis[J]. Neurosci Biobehav Rev, 2016, 65: 185-194.
[6]	Sutterland AL, Fond G, Kuin A, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis[J]. Acta Psychiatr Scand, 2015, 132(3): 161-179.
[7]	Contini C, Seraceni S, Cultrera R, et al. Evaluation of a Real-time PCR-based assay using the lightcycler system for detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients with toxoplasmic retinochoroiditis[J]. Int J Parasitol, 2005, 35(3): 275-283.
[8]	Wam EC, Sama LF, Ali IM, et al. Seroprevalence of Toxoplasma gondii IgG and IgM antibodies and associated risk factors in women of child-bearing age in Njinikom, NW Cameroon[J]. BMC Res Notes, 2016, 9(1): 406.
[9]	Torrey EF, Bartko JJ, Lun ZR, et al. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis[J]. Schizophr Bull, 2007, 33(3): 729-736.
[10]	Torrey EF, Bartko JJ, Yolken RH.Toxoplasma gondii and other risk factors for schizophrenia: an update[J]. Schizophr Bull, 2012, 38(3): 642-647.
[11]	Monroe JM, Buckley PF, Miller BJ.Meta-analysis of anti-Toxoplasma gondii IgM antibodies in acute psychosis[J]. Schizophr Bull, 2015, 41(4): 989-998.
[12]	Brown AS, Patterson PH.Maternal infection and schizophrenia: implications for prevention[J]. Schizophr Bull, 2011, 37(2): 284-290.
[13]	Fuglewicz AJ, Piotrowski P, Stodolak A.Relationship between toxoplasmosis and schizophrenia: a review[J]. Adv Clin Exp Med, 2017, 26(6): 1031-1036.
[14]	Brown AS, Schaefer CA, Quesenberry CP Jr, et al. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring[J]. Am J Psychiatry, 2005, 162(4): 767-773.
[15]	Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth[J]. Biol Psychiatry, 2007, 61(5): 688-693.
[16]	Blanchard N, Dunay IR, Schlüter D.Persistence of Toxoplasma gondii in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system[J]. Parasite Immunol, 2015, 37(3): 150-158.
[17]	Torrey EF, Yolken RH.Schizophrenia and toxoplasmosis[J]. Schizophr Bull, 2007, 33(3): 727-728.
[18]	Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Early infections of Toxoplasma gondii and the later development of schizophrenia[J]. Schizophr Bull, 2007, 33(3): 741-744.
[19]	Pedersen MG, Mortensen PB, Norgaard-Pedersen B, et al. Toxoplasma gondii infection and self-directed violence in mothers[J]. Arch Gen Psychiatry, 2012, 69(11): 1123-1130.
[20]	Holub D, Flegr J, Dragomirecká E, et al. Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia[J]. Acta Psychiatr Scand, 2013, 127(3): 227-238.
[21]	申连城, 李遵清, 刘娟美. 弓形虫抗体阳性与阴性精神分裂症患者临床症状差异性研究[J]. 中国病原生物学杂志, 2014, 9(9): 842-844.
[22]	Carruthers VB, Suzuki Y.Effects of Toxoplasma gondii infection on the brain[J]. Schizophr Bull, 2007, 33(3): 745-751.
[23]	Hermes G, Ajioka JW, Kelly KA, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection[J]. J Neuroinflammation, 2008, 5: 48.
[24]	Lachenmaier SM, Deli MA, Meissner M, et al. Intracellular transport of Toxoplasma gondii through the blood-brain barrier[J]. J Neuroimmunol, 2011, 232(1-2): 119-130.
[25]	Berenreiterová M, Flegr J, Kuběna AA, et al. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis[J]. PLoS One, 2011, 6(12): e28925.
[26]	Parlog A, Harsan LA, Zagrebelsky M, et al. Chronic murine toxoplasmosis is defined by subtle changes in neuronal connectivity[J]. Dis Model Mech, 2014, 7(4): 459-469.
[27]	Toda M, Abi-Dargham A.Dopamine hypothesis of schizophrenia: making sense of it all[J]. Curr Psychiatry Rep, 2007, 9(4): 329-336.
[28]	Eggers AE.A serotonin hypothesis of schizophrenia[J]. Med Hypotheses, 2013, 80(6): 791-794.
[29]	Tedford E, Mcconkey G.Neurophysiological changes induced by chronic Toxoplasma gondii infection[J]. Pathogens, 2017, 6(2): 19.
[30]	Prandovszky E, Gaskell E, Martin H, et al. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism[J]. PLoS One, 2011, 6(9): e23866.
[31]	Elsheikha HM, Büsselberg D, Zhu XQ.The known and missing links between Toxoplasma gondii and schizophrenia[J]. Metab Brain Dis, 2016, 31(4): 749-759.
[32]	Wang ZT, Verma SK, Dubey JP, et al. The aromatic amino acid hydroxylase genes AAH1 and AAH2 in Toxoplasma gondii contribute to transmission in the cat[J]. PLoS Pathog, 2017, 13(3): e1006272.
[33]	Mahmoud ME, Ihara F, Fereig RM, et al. Induction of depression-related behaviors by reactivation of chronic Toxoplasma gondii infection in mice[J]. Behav Brain Res, 2016, 298(Pt B): 125-133.
[34]	Brooks JM, Carrillo GL, Su J, et al. Toxoplasma gondii infections alter GABAergic synapses and signaling in the central nervous system[J]. MBio, 2015, 6(6): e01428-e01415.
[35]	Anders S, Kinney DK.Abnormal immune system development and function in schizophrenia helps reconcile diverse findings and suggests new treatment and prevention strategies[J]. Brain Res, 2015, 161: 93-112.
[36]	Borovcanin MM, Jovanovic I, Radosavljevic G, et al. Interleukin-6 in schizophrenia-is there a therapeutic relevance[J]. Front Psychiatry, 2017, 8: 221.
[37]	Frydecka D, Misiak B, Pawlak-Adamska E, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation[J]. Eur Arch Psychiatry Clin Neurosci, 2015, 265(6): 449-459.
[38]	Matowicka-Karna J, Dymicka-Piekarska V, Kemona H.Does Toxoplasma gondii infection affect the levels of IgE and cytokines (IL-5, IL-6, IL-10, IL-12, and TNF-alpha)[J]. Clin Dev Immunol, 2009, 2009: 374696.